Viatris Inc. (VTRS)
NASDAQ • Healthcare
Last close at October 2, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Viatris Inc. currently loses $3.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 32 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Viatris Inc. beat on both the top and bottom line in the second fiscal quarter of 2026, based on preliminary results reported Aug. 6. Revenue rose 4.9% to about $3.8 billion, topping the about $3.7 billion consensus by 2.2%, while gross margin held near 39% and gross profit reached about $1.5 billion. Adjusted EPS of $0.69 beat the $0.60 estimate by 14.8% and improved 11.3% from $0.62 a year ago, while net income came in at negative about $119 million, down 2482.6% from negative $4.6 million a year ago. Brands, the largest segment, generated about $2.3 billion, up 10.2% year over year. Operating cash flow totaled about $770 million, and Viatris repurchased about $150 million of stock and paid about $279 million in dividends. Consensus for the next period calls for EPS of $0.65 on revenue of $3.82 billion.
About Viatris Inc.
Viatris Inc. operates in healthcare as a maker of branded, generic, and specialty medicines, trading on NASDAQ under VTRS. Its portfolio spans treatments from Lyrica and Lipitor to biosimilars and raw pharmaceutical ingredients, and it generated $14.3 billion of revenue in FY2025.
Today's Snapshot
The day ended with VTRS 0.8% higher at 17.60, while its sector was flat. VTRS closed within 4.5% of its 52-week high of 18.43.
Trading Volume
Below 10d avg (9.7M)
7.2M
vs S&P 500 Today
Inline with Market
+0.02%
Updated: October 2, 2026 at 20:15 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$15.00 - $17.55Buy
- RSI (14)57.35Neutral
- Stochastic %K (14, 3, 3)59.52Neutral
- MACD Level (12, 26)0.29Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.